View Item 

Show simple item record

Advances in predicting acute GVHD

dc.contributor.authorHarris, Andrew C.en_US
dc.contributor.authorFerrara, James L. M.en_US
dc.contributor.authorLevine, John E.en_US
dc.date.accessioned2013-02-12T19:00:33Z
dc.date.available2014-04-02T15:08:08Zen_US
dc.date.issued2013-02en_US
dc.identifier.citationHarris, Andrew C.; Ferrara, James L. M.; Levine, John E. (2013). "Advances in predicting acute GVHD ." British Journal of Haematology 160(3): 288-302. <http://hdl.handle.net/2027.42/96282>en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/96282
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherBiomarkersen_US
dc.subject.otherPredictionen_US
dc.subject.otherBone Marrow Transplant Immunologyen_US
dc.subject.otherGraft‐Versus‐Host Diseaseen_US
dc.subject.otherBone Marrow Transplanten_US
dc.titleAdvances in predicting acute GVHDen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23205489en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/96282/1/bjh12142.pdf
dc.identifier.doi10.1111/bjh.12142en_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceRezvani, K., Mielke, S., Ahmadzadeh, M., Kilical, Y., Savani, B.N., Zeilah, J., Keyvanfar, K., Montero, A., Hensel, N., Kurlander, R. & Barrett, A.J. ( 2006 ) High donor FOXP3‐positive regulatory T‐cell (Treg) content is associated with a low risk of GVHD following HLA‐matched allogeneic SCT. Blood, 108, 1291 – 1297.en_US
dc.identifier.citedreferenceSarin, R., Wu, X. & Abraham, C. ( 2011 ) Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T‐cell functional responses. Proceedings of the National Academy of Sciences of the United States of America, 108, 9560 – 9565.en_US
dc.identifier.citedreferenceShaw, B.E., Gooley, T.A., Malkki, M., Madrigal, J.A., Begovich, A.B., Horowitz, M.M., Gratwohl, A., Ringden, O., Marsh, S.G. & Petersdorf, E.W. ( 2007 ) The importance of HLA‐DPB1 in unrelated donor hematopoietic cell transplantation. Blood, 110, 4560 – 4566.en_US
dc.identifier.citedreferenceSocie, G., Loiseau, P., Tamouza, R., Janin, A., Busson, M., Gluckman, E. & Charron, D. ( 2001 ) Both genetic and clinical factors predict the development of graft‐versus‐host disease after allogeneic hematopoietic stem cell transplantation. Transplantation, 72, 699 – 706.en_US
dc.identifier.citedreferenceSoiffer, R.J., Lerademacher, J., Ho, V., Kan, F., Artz, A., Champlin, R.E., Devine, S., Isola, L., Lazarus, H.M., Marks, D.I., Porter, D.L., Waller, E.K., Horowitz, M.M. & Eapen, M. ( 2011 ) Impact of immune modulation with anti‐T‐cell antibodies on the outcome of reduced‐intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood, 117, 6963 – 6970.en_US
dc.identifier.citedreferenceStern, M., Passweg, J.R., Locasciulli, A., Socie, G., Schrezenmeier, H., Bekassy, A.N., Fuehrer, M., Hows, J., Korthof, E.T., McCann, S., Tichelli, A., Zoumbos, N.C., Marsh, J.C., Bacigalupo, A. & Gratwohl, A. ( 2006 ) Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation, 82, 218 – 226.en_US
dc.identifier.citedreferenceStorb, R. & Thomas, E.D. ( 1985 ) Graft‐versus‐host disease in dog and man: the Seattle experience. Immunological Reviews, 88, 215 – 238.en_US
dc.identifier.citedreferenceSuarez, A., Castro, P., Alonso, R., Mozo, L. & Gutierrez, C. ( 2003 ) Interindividual variations in constitutive interleukin‐10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation, 75, 711 – 717.en_US
dc.identifier.citedreferenceThiant, S., Yakoub‐Agha, I., Magro, L., Trauet, J., Coiteux, V., Jouet, J.P., Dessaint, J.P. & Labalette, M. ( 2010 ) Plasma levels of IL‐7 and IL‐15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplantation, 45, 1546 – 1552.en_US
dc.identifier.citedreferenceThiant, S., Labalette, M., Trauet, J., Coiteux, V., de Berranger, E., Dessaint, J.P. & Yakoub‐Agha, I. ( 2011 ) Plasma levels of IL‐7 and IL‐15 after reduced intensity conditioned allo‐SCT and relationship to acute GVHD. Bone Marrow Transplantation, 46, 1374 – 1381.en_US
dc.identifier.citedreferenceUitterlinden, A.G., Fang, Y., Van Meurs, J.B., Pols, H.A. & Van Leeuwen, J.P. ( 2004 ) Genetics and biology of vitamin D receptor polymorphisms. Gene, 338, 143 – 156.en_US
dc.identifier.citedreferenceUrbano‐Ispizua, A., Rozman, C., Pimentel, P., Solano, C., de la Rubia, J., Brunet, S., Perez‐Oteyza, J., Ferra, C., Zuazu, J., Caballero, D., Bargay, J., Carvalhais, A., Diez, J.L., Espigado, I., Alegre, A., Rovira, M., Campilho, F., Odriozola, J., Sanz, M.A., Sierra, J., Garcia‐Conde, J. & Montserrat, E. ( 2002 ) Risk factors for acute graft‐versus‐host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA‐identical siblings. Blood, 100, 724 – 727.en_US
dc.identifier.citedreferencevan der Velden, W.J., Donnelly, J.P. & Blijlevens, N.M. ( 2011 ) Differences in T cell depletion and intestinal mucositis explain inconsistent effects of NOD2/CARD15 polymophisms in SCT. Biology of blood and marrow transplantation, 17, 1421 – 1423.en_US
dc.identifier.citedreferenceVerrier, T., Solhonne, B., Sallenave, J.M. & Garcia‐Verdugo, I. ( 2012 ) The WAP protein Trappin‐2/Elafin: a handyman in the regulation of inflammatory and immune responses. International Journal of Biochemistry & Cell Biology, 44, 1377 – 1380.en_US
dc.identifier.citedreferenceWalters, S., Webster, K.E., Sutherland, A., Gardam, S., Groom, J., Liuwantara, D., Marino, E., Thaxton, J., Weinberg, A., Mackay, F., Brink, R., Sprent, J. & Grey, S.T. ( 2009 ) Increased CD4+ Foxp3+ T cells in BAFF‐transgenic mice suppress T cell effector responses. Journal of Immunoly, 182, 793 – 801.en_US
dc.identifier.citedreferenceWang, Z., Sorror, M.L., Leisenring, W., Schoch, G., Maloney, D.G., Sandmaier, B.M. & Storb, R. ( 2010 ) The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. British Journal of Haematology, 149, 101 – 110.en_US
dc.identifier.citedreferenceWeissinger, E.M., Schiffer, E., Hertenstein, B., Ferrara, J.L., Holler, E., Stadler, M., Kolb, H.J., Zander, A., Zurbig, P., Kellmann, M. & Ganser, A. ( 2007 ) Proteomic patterns predict acute graft‐versus‐host disease after allogeneic hematopoietic stem cell transplantation. Blood, 109, 5511 – 5519.en_US
dc.identifier.citedreferenceWermke, M., Maiwald, S., Schmelz, R., Thiede, C., Schetelig, J., Ehninger, G., Bornhauser, M. & Wassmuth, R. ( 2010 ) Genetic variations of interleukin‐23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft‐versus‐host disease after allogeneic transplantation. Biology of blood and marrow transplantation, 16, 1718 – 1727.en_US
dc.identifier.citedreferenceWillems, E., Humblet‐Baron, S., Dengis, O., Seidel, L., Beguin, Y. & Baron, F. ( 2010 ) Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft‐versus‐host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 1442 – 1448.en_US
dc.identifier.citedreferenceWolf, D., Wolf, A.M., Fong, D., Rumpold, H., Strasak, A., Clausen, J. & Nachbaur, D. ( 2007 ) Regulatory T‐cells in the graft and the risk of acute graft‐versus‐host disease after allogeneic stem cell transplantation. Transplantation, 83, 1107 – 1113.en_US
dc.identifier.citedreferenceWoolfrey, A., Klein, J.P., Haagenson, M., Spellman, S., Petersdorf, E., Oudshoorn, M., Gajewski, J., Hale, G.A., Horan, J., Battiwalla, M., Marino, S.R., Setterholm, M., Ringden, O., Hurley, C., Flomenberg, N., Anasetti, C., Fernandez‐Vina, M. & Lee, S.J. ( 2011 ) HLA‐C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biology of blood and marrow transplantation, 17, 885 – 892.en_US
dc.identifier.citedreferenceAlousi, A.M., Weisdorf, D.J., Logan, B.R., Bolanos‐Meade, J., Carter, S., Difronzo, N., Pasquini, M., Goldstein, S.C., Ho, V.T., Hayes‐Lattin, B., Wingard, J.R., Horowitz, M.M. & Levine, J.E. ( 2009 ) Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood, 114, 511 – 517.en_US
dc.identifier.citedreferenceAmbruzova, Z., Mrazek, F., Raida, L., Jindra, P., Vidan‐Jeras, B., Faber, E., Pretnar, J., Indrak, K. & Petrek, M. ( 2009 ) Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 44, 227 – 235.en_US
dc.identifier.citedreferenceAnasetti, C., Logan, B.R., Lee, S.J., Waller, E.K., Weisdorf, D.J., Wingard, J.R., Cutler, C.S., Westervelt, P., Woolfrey, A., Couban, S., Johnston, L., Maziarz, R.T., Pulsipher, M., Anderlini, P., Bensinger, W.I., Leitman, S.F., Rowley, S.D., Carter, S.L., Horowitz, M.M. & Confer, D.L. ( 2011 ) Increased Incidence of Chronic Graft‐Versus‐Host Disease (GVHD) and No Survival Advantage with Filgrastim‐Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. Blood (ASH Annual Meeting Abstracts), 118, 1.en_US
dc.identifier.citedreferenceAnasetti, C., Aversa, F. & Brunstein, C.G. ( 2012 ) Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? Biology of blood and marrow transplantation, 18, S161 – S165.en_US
dc.identifier.citedreferenceArora, M., Weisdorf, D.J., Spellman, S.R., Haagenson, M.D., Klein, J.P., Hurley, C.K., Selby, G.B., Antin, J.H., Kernan, N.A., Kollman, C., Nademanee, A., McGlave, P., Horowitz, M.M. & Petersdorf, E.W. ( 2009 ) HLA‐identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. Journal of Clinical Oncology, 27, 1644 – 1652.en_US
dc.identifier.citedreferenceAugust, K.J., Chiang, K.Y., Bostick, R.M., Flanders, W.D., Waller, E.K., Langston, A., Worthington‐White, D., Rowland, P., Moore, K.F., Khoury, H.J. & Horan, J.T. ( 2011 ) Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplantation, 46, 601 – 604.en_US
dc.identifier.citedreferenceBertinetto, F.E., Dall'Omo, A.M., Mazzola, G.A., Rendine, S., Berrino, M., Bertola, L., Magistroni, P., Caropreso, P., Falda, M., Locatelli, F., Busca, A. & Amoroso, A. ( 2006 ) Role of non‐HLA genetic polymorphisms in graft‐versus‐host disease after haematopoietic stem cell transplantation. International Journal of Immunogenetics, 33, 375 – 384.en_US
dc.identifier.citedreferenceBogunia‐Kubik, K., Middleton, P., Norden, J., Dickinson, A. & Lange, A. ( 2008 ) Association of vitamin D receptor polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. International Journal of Immunogenetics, 35, 207 – 213.en_US
dc.identifier.citedreferenceBoyman, O., Krieg, C., Homann, D. & Sprent, J. ( 2012 ) Homeostatic maintenance of T cells and natural killer cells. Cellular and Molecular Life Sciences, 69, 1597 – 1608.en_US
dc.identifier.citedreferenceBurroughs, L.M., O'Donnell, P.V., Sandmaier, B.M., Storer, B.E., Luznik, L., Symons, H.J., Jones, R.J., Ambinder, R.F., Maris, M.B., Blume, K.G., Niederwieser, D.W., Bruno, B., Maziarz, R.T., Pulsipher, M.A., Petersen, F.B., Storb, R., Fuchs, E.J. & Maloney, D.G. ( 2008 ) Comparison of outcomes of HLA‐matched related, unrelated, or HLA‐haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biology of blood and marrow transplantation, 14, 1279 – 1287.en_US
dc.identifier.citedreferenceCash, H.L., Whitham, C.V., Behrendt, C.L. & Hooper, L.V. ( 2006 ) Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science, 313, 1126 – 1130.en_US
dc.identifier.citedreferenceCavet, J., Dickinson, A.M., Norden, J., Taylor, P.R., Jackson, G.H. & Middleton, P.G. ( 2001 ) Interferon‐gamma and interleukin‐6 gene polymorphisms associate with graft‐versus‐host disease in HLA‐matched sibling bone marrow transplantation. Blood, 98, 1594 – 1600.en_US
dc.identifier.citedreferenceCho, B.S., Min, C.K., Kim, H.J., Lee, S., Kim, Y.J., Lim, J.Y., Jeong, D.C., Cho, B., Kim, H.K., Eom, K.S., Cho, S.G., Kim, D.W., Lee, J.W., Min, W.S., Kim, C.C. & Chung, N.G. ( 2010 ) High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft‐versus‐host disease following myeloablative allogeneic stem cell transplantation. Biology of blood and marrow transplantation, 16, 629 – 638.en_US
dc.identifier.citedreferenceCho, B.S., Yoon, J.H., Shin, S.H., Yahng, S.A., Lee, S.E., Eom, K.S., Kim, Y.J., Lee, S., Min, C.K., Cho, S.G., Kim, D.W., Lee, J.W., Min, W.S., Park, C.W. & Kim, H.J. ( 2012 ) Comparison of allogeneic stem cell transplantation from familial‐mismatched/haploidentical donors and from unrelated donors in adults with high‐risk acute myelogenous leukemia. Biology of blood and marrow transplantation, 18, 1552 – 1563.en_US
dc.identifier.citedreferenceChoi, S.W., Kitko, C.L., Braun, T., Paczesny, S., Yanik, G., Mineishi, S., Krijanovski, O., Jones, D., Whitfield, J., Cooke, K., Hutchinson, R.J., Ferrara, J.L.M. & Levine, J.E. ( 2008 ) Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood, 112, 1539 – 1542.en_US
dc.identifier.citedreferenceChoi, S.W., Stiff, P., Cooke, K., Ferrara, J.L., Braun, T., Kitko, C., Reddy, P., Yanik, G., Mineishi, S., Paczesny, S., Hanauer, D., Pawarode, A., Peres, E., Rodriguez, T., Smith, S. & Levine, J.E. ( 2012 ) TNF‐Inhibition with Etanercept for Graft‐versus‐Host Disease Prevention in High‐Risk HCT: lower TNFR1 Levels Correlate with Better Outcomes. Biology of blood and marrow transplantation, 18, 1525 – 1532.en_US
dc.identifier.citedreferenceCouriel, D.R., Saliba, R.M., Giralt, S., Khouri, I., Andersson, B.S., de Lima, M., Hosing, C., Anderlini, P., Donato, M., Cleary, K., Gajewski, J., Neumann, J., Ippoliti, C., Rondon, G., Cohen, A. & Champlin, R. ( 2004a ) Acute and chronic graft‐versus‐host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of blood and marrow transplantation, 10, 178 – 185.en_US
dc.identifier.citedreferenceCouriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., Anderlini, P., Kontoyiannis, D.P., Cohen, A., Martin, T., Giralt, S. & Champlin, R. ( 2004b ) Tumor necrosis factor‐alpha blockade for the treatment of acute GVHD. Blood, 104, 649 – 654.en_US
dc.identifier.citedreferenceCullup, H., Dickinson, A.M., Jackson, G.H., Taylor, P.R., Cavet, J. & Middleton, P.G. ( 2001 ) Donor interleukin 1 receptor antagonist genotype associated with acute graft‐versus‐host disease in human leucocyte antigen‐matched sibling allogeneic transplants. British Journal of Haematology, 113, 807 – 813.en_US
dc.identifier.citedreferenceDean, R.M., Fry, T., Mackall, C., Steinberg, S.M., Hakim, F., Fowler, D., Odom, J., Foley, J., Gress, R. & Bishop, M.R. ( 2008 ) Association of serum interleukin‐7 levels with the development of acute graft‐versus‐host disease. Journal of Clinical Oncology, 26, 5735 – 5741.en_US
dc.identifier.citedreferenceDeeg, H.J. ( 2007 ) How I treat refractory acute GVHD. Blood, 109, 4119 – 4126.en_US
dc.identifier.citedreferenceDuvallet, E., Semerano, L., Assier, E., Falgarone, G. & Boissier, M.C. ( 2011 ) Interleukin‐23: a key cytokine in inflammatory diseases. Annals of Medicine, 43, 503 – 511.en_US
dc.identifier.citedreferenceEapen, M., Rubinstein, P., Zhang, M.J., Stevens, C., Kurtzberg, J., Scaradavou, A., Loberiza, F.R., Champlin, R.E., Klein, J.P., Horowitz, M.M. & Wagner, J.E. ( 2007 ) Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, 369, 1947 – 1954.en_US
dc.identifier.citedreferenceEapen, M., Klein, J.P., Sanz, G.F., Spellman, S., Ruggeri, A., Anasetti, C., Brown, M., Champlin, R.E., Garcia‐Lopez, J., Hattersely, G., Koegler, G., Laughlin, M.J., Michel, G., Nabhan, S.K., Smith, F.O., Horowitz, M.M., Gluckman, E. & Rocha, V. ( 2011 ) Effect of donor‐recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical‐cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. The lancet oncology, 12, 1214 – 1221.en_US
dc.identifier.citedreferenceElmaagacli, A.H., Koldehoff, M., Hindahl, H., Steckel, N.K., Trenschel, R., Peceny, R., Ottinger, H., Rath, P.M., Ross, R.S., Roggendorf, M., Grosse‐Wilde, H. & Beelen, D.W. ( 2006 ) Mutations in innate immune system NOD2/CARD 15 and TLR‐4 (Thr399Ile) genes influence the risk for severe acute graft‐versus‐host disease in patients who underwent an allogeneic transplantation. Transplantation, 81, 247 – 254.en_US
dc.identifier.citedreferenceElmaagacli, A.H., Koldehoff, M., Landt, O. & Beelen, D.W. ( 2008 ) Relation of an interleukin‐23 receptor gene polymorphism to graft‐versus‐host disease after hematopoietic‐cell transplantation. Bone Marrow Transplantation, 41, 821 – 826.en_US
dc.identifier.citedreferenceFerrara, J.L., Levine, J.E., Reddy, P. & Holler, E. ( 2009 ) Graft‐versus‐host disease. Lancet, 373, 1550 – 1561.en_US
dc.identifier.citedreferenceFerrara, J.L., Harris, A.C., Greenson, J.K., Braun, T.M., Holler, E., Teshima, T., Levine, J.E., Choi, S.W., Huber, E., Landfried, K., Akashi, K., Vander Lugt, M., Reddy, P., Chin, A., Zhang, Q., Hanash, S. & Paczesny, S. ( 2011 ) Regenerating islet‐derived 3‐alpha is a biomarker of gastrointestinal graft‐versus‐host disease. Blood, 118, 6702 – 6708.en_US
dc.identifier.citedreferenceFlomenberg, N., Baxter‐Lowe, L.A., Confer, D., Fernandez‐Vina, M., Filipovich, A., Horowitz, M., Hurley, C., Kollman, C., Anasetti, C., Noreen, H., Begovich, A., Hildebrand, W., Petersdorf, E., Schmeckpeper, B., Setterholm, M., Trachtenberg, E., Williams, T., Yunis, E. & Weisdorf, D. ( 2004 ) Impact of HLA class I and class II high‐resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA‐C mismatching is associated with a strong adverse effect on transplantation outcome. Blood, 104, 1923 – 1930.en_US
dc.identifier.citedreferenceFlowers, M.E., Inamoto, Y., Carpenter, P.A., Lee, S.J., Kiem, H.P., Petersdorf, E.W., Pereira, S.E., Nash, R.A., Mielcarek, M., Fero, M.L., Warren, E.H., Sanders, J.E., Storb, R.F., Appelbaum, F.R., Storer, B.E. & Martin, P.J. ( 2011 ) Comparative analysis of risk factors for acute graft‐versus‐host disease and for chronic graft‐versus‐host disease according to National Institutes of Health consensus criteria. Blood, 117, 3214 – 3219.en_US
dc.identifier.citedreferenceGeyer, M.B., Jacobson, J.S., Freedman, J., George, D., Moore, V., van de Ven, C., Satwani, P., Bhatia, M., Garvin, J.H., Bradley, M.B., Harrison, L., Morris, E., Della‐Latta, P., Schwartz, J., Baxter‐Lowe, L.A. & Cairo, M.S. ( 2011 ) A comparison of immune reconstitution and graft‐versus‐host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. British Journal of Haematology, 155, 218 – 234.en_US
dc.identifier.citedreferenceGoussetis, E., Varela, I., Peristeri, I., Kitra, V., Spanou, K., Moraloglou, O., Paisiou, A., Karatasaki, S., Soldatou, A., Constantinidou, N. & Graphakos, S. ( 2011 ) Cytokine gene polymorphisms and graft‐versus‐host disease in children after matched sibling hematopoietic stem cell transplantation: a single‐center experience. Cellular & Molecular Immunology, 8, 276 – 280.en_US
dc.identifier.citedreferenceGoyal, R.K., Lin, Y., Schultz, K.R., Ferrell, R.E., Kim, Y., Fairfull, L., Livote, E., Yanik, G. & Atlas, M. ( 2010 ) Tumor necrosis factor‐alpha gene polymorphisms are associated with severity of acute graft‐versus‐host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study. Biology of blood and marrow transplantation, 16, 927 – 936.en_US
dc.identifier.citedreferenceGruhn, B., Intek, J., Pfaffendorf, N., Zell, R., Corbacioglu, S., Zintl, F., Beck, J.F., Debatin, K.M. & Steinbach, D. ( 2009 ) Polymorphism of interleukin‐23 receptor gene but not of NOD2/CARD15 is associated with graft‐versus‐host disease after hematopoietic stem cell transplantation in children. Biology of blood and marrow transplantation, 15, 1571 – 1577.en_US
dc.identifier.citedreferenceHahn, T., McCarthy, P.L. Jr., Zhang, M.J., Wang, D., Arora, M., Frangoul, H., Gale, R.P., Hale, G.A., Horan, J., Isola, L., Maziarz, R.T., van Rood, J.J., Gupta, V., Halter, J., Reddy, V., Tiberghien, P., Litzow, M., Anasetti, C., Pavletic, S. & Ringden, O. ( 2008 ) Risk factors for acute graft‐versus‐host disease after human leukocyte antigen‐identical sibling transplants for adults with leukemia. Journal of Clinical Oncology, 26, 5728 – 5734.en_US
dc.identifier.citedreferenceHill, G.R. & Ferrara, J.L. ( 2000 ) The primacy of the gastrointestinal tract as a target organ of acute graft‐versus‐host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood, 95, 2754 – 2759.en_US
dc.identifier.citedreferenceHippen, K.L., Riley, J.L., June, C.H. & Blazar, B.R. ( 2011 ) Clinical perspectives for regulatory T cells in transplantation tolerance. Seminars in Immunology, 23, 462 – 468.en_US
dc.identifier.citedreferenceHoller, E., Rogler, G., Herfarth, H., Brenmoehl, J., Wild, P.J., Hahn, J., Eissner, G., Scholmerich, J. & Andreesen, R. ( 2004 ) Both donor and recipient NOD2/CARD15 mutations associate with transplant‐related mortality and GvHD following allogeneic stem cell transplantation. Blood, 104, 889 – 894.en_US
dc.identifier.citedreferenceHoller, E., Rogler, G., Brenmoehl, J., Hahn, J., Greinix, H., Dickinson, A.M., Socie, G., Wolff, D., Finke, J., Fischer, G., Jackson, G., Rocha, V., Hilgendorf, I., Eissner, G., Marienhagen, J. & Andreesen, R. ( 2008 ) The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. International Journal of Immunogenetics, 35, 381 – 384.en_US
dc.identifier.citedreferenceHurme, M. & Santtila, S. ( 1998 ) IL‐1 receptor antagonist (IL‐1Ra) plasma levels are co‐ordinately regulated by both IL‐1Ra and IL‐1beta genes. European Journal of Immunology, 28, 2598 – 2602.en_US
dc.identifier.citedreferenceJagasia, M., Arora, M., Flowers, M.E., Chao, N.J., McCarthy, P.L., Cutler, C.S., Urbano‐Ispizua, A., Pavletic, S.Z., Haagenson, M.D., Zhang, M.J., Antin, J.H., Bolwell, B.J., Bredeson, C., Cahn, J.Y., Cairo, M., Gale, R.P., Gupta, V., Lee, S.J., Litzow, M., Weisdorf, D.J., Horowitz, M.M. & Hahn, T. ( 2012 ) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 119, 296 – 307.en_US
dc.identifier.citedreferenceKarabon, L., Wysoczanska, B., Bogunia‐Kubik, K., Suchnicki, K. & Lange, A. ( 2005 ) IL‐6 and IL‐10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft‐versus‐host disease. Human Immunology, 66, 700 – 710.en_US
dc.identifier.citedreferenceKitko, C.L., Paczesny, S., Yanik, G., Braun, T., Jones, D., Whitfield, J., Choi, S.W., Hutchinson, R.J., Ferrara, J.L. & Levine, J.E. ( 2008 ) Plasma elevations of tumor necrosis factor‐receptor‐1 at day 7 postallogeneic transplant correlate with graft‐versus‐host disease severity and overall survival in pediatric patients. Biology of blood and marrow transplantation, 14, 759 – 765.en_US
dc.identifier.citedreferenceLaughlin, M.J., Eapen, M., Rubinstein, P., Wagner, J.E., Zhang, M.J., Champlin, R.E., Stevens, C., Barker, J.N., Gale, R.P., Lazarus, H.M., Marks, D.I., van Rood, J.J., Scaradavou, A. & Horowitz, M.M. ( 2004 ) Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. New England Journal of Medicine, 351, 2265 – 2275.en_US
dc.identifier.citedreferenceLee, S.J., Klein, J., Haagenson, M., Baxter‐Lowe, L.A., Confer, D.L., Eapen, M., Fernandez‐Vina, M., Flomenberg, N., Horowitz, M., Hurley, C.K., Noreen, H., Oudshoorn, M., Petersdorf, E., Setterholm, M., Spellman, S., Weisdorf, D., Williams, T.M. & Anasetti, C. ( 2007 ) High‐resolution donor‐recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood, 110, 4576 – 4583.en_US
dc.identifier.citedreferenceLevine, J.E., Paczesny, S., Mineishi, S., Braun, T., Choi, S.W., Hutchinson, R.J., Jones, D., Khaled, Y., Kitko, C.L., Bickley, D., Krijanovski, O., Reddy, P., Yanik, G. & Ferrara, J.L.M. ( 2008 ) Etanercept plus methylprednisolone as initial therapy for acute graft‐versus‐host disease. Blood, 111, 2470 – 2475.en_US
dc.identifier.citedreferenceLevine, J.E., Logan, B.R., Wu, J., Alousi, A.M., Bolanos‐Meade, J., Ferrara, J.L., Ho, V.T., Weisdorf, D.J. & Paczesny, S. ( 2012 ) Acute graft‐versus‐host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood, 119, 3854 – 3860.en_US
dc.identifier.citedreferenceLin, M.T., Storer, B., Martin, P.J., Tseng, L.H., Gooley, T., Chen, P.J. & Hansen, J.A. ( 2003 ) Relation of an interleukin‐10 promoter polymorphism to graft‐versus‐host disease and survival after hematopoietic‐cell transplantation. New England Journal of Medicine, 349, 2201 – 2210.en_US
dc.identifier.citedreferenceLiu, D., Yan, C., Xu, L., Wang, Y., Han, W., Zhang, X., Liu, K. & Huang, X. ( 2010 ) Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft‐versus‐host disease through systemic release of inflammatory cytokines. Biology of blood and marrow transplantation, 16, 1567 – 1575.en_US
dc.identifier.citedreferenceLoiseau, P., Busson, M., Balere, M.L., Dormoy, A., Bignon, J.D., Gagne, K., Gebuhrer, L., Dubois, V., Jollet, I., Bois, M., Perrier, P., Masson, D., Moine, A., Absi, L., Reviron, D., Lepage, V., Tamouza, R., Toubert, A., Marry, E., Chir, Z., Jouet, J.P., Blaise, D., Charron, D. & Raffoux, C. ( 2007 ) HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA‐A, ‐B, ‐C, ‐DRB1, or ‐DQB1 is strongly associated with overall survival. Biology of blood and marrow transplantation, 13, 965 – 974.en_US
dc.identifier.citedreferenceLudajic, K., Balavarca, Y., Bickeboller, H., Rosenmayr, A., Fischer, G.F., Fae, I., Kalhs, P., Pohlreich, D., Kouba, M., Dobrovolna, M. & Greinix, H.T. ( 2009 ) Minor ABO‐mismatches are risk factors for acute graft‐versus‐host disease in hematopoietic stem cell transplant patients. Biology of blood and marrow transplantation, 15, 1400 – 1406.en_US
dc.identifier.citedreferenceMacMillan, M.L., Radloff, G.A., DeFor, T.E., Weisdorf, D.J. & Davies, S.M. ( 2003 ) Interleukin‐1 genotype and outcome of unrelated donor bone marrow transplantation. British Journal of Haematology, 121, 597 – 604.en_US
dc.identifier.citedreferenceMacMillan, M.L., Weisdorf, D.J., Brunstein, C.G., Cao, Q., DeFor, T.E., Verneris, M.R., Blazar, B.R. & Wagner, J.E. ( 2009 ) Acute graft‐versus‐host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood, 113, 2410 – 2415.en_US
dc.identifier.citedreferenceMattsson, J., Westin, S., Edlund, S. & Remberger, M. ( 2006 ) Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft‐versus‐host disease. Bone Marrow Transplantation, 38, 629 – 633.en_US
dc.identifier.citedreferenceMehta, P.A., Eapen, M., Klein, J.P., Gandham, S., Elliott, J., Zamzow, T., Combs, M., Aplenc, R., MacMillan, M.L., Weisdorf, D.J., Petersdorf, E. & Davies, S.M. ( 2007 ) Interleukin‐1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. British Journal of Haematology, 137, 152 – 157.en_US
dc.identifier.citedreferenceMiddleton, P.G., Taylor, P.R., Jackson, G., Proctor, S.J. & Dickinson, A.M. ( 1998 ) Cytokine gene polymorphisms associating with severe acute graft‐versus‐host disease in HLA‐identical sibling transplants. Blood, 92, 3943 – 3948.en_US
dc.identifier.citedreferenceMiddleton, P.G., Cullup, H., Dickinson, A.M., Norden, J., Jackson, G.H., Taylor, P.R. & Cavet, J. ( 2002 ) Vitamin D receptor gene polymorphism associates with graft‐versus‐host disease and survival in HLA‐matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplantation, 30, 223 – 228.en_US
dc.identifier.citedreferenceMiddleton, P.G., Norden, J., Cullup, H., Cavet, J., Jackson, G.H., Taylor, P.R. & Dickinson, A.M. ( 2003 ) Oestrogen receptor alpha gene polymorphism associates with occurrence of graft‐versus‐host disease and reduced survival in HLA‐matched sib‐allo BMT. Bone Marrow Transplantation, 32, 41 – 47.en_US
dc.identifier.citedreferenceMiklos, D.B., Kim, H.T., Zorn, E., Hochberg, E.P., Guo, L., Mattes‐Ritz, A., Viatte, S., Soiffer, R.J., Antin, J.H. & Ritz, J. ( 2004 ) Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood, 103, 353 – 359.en_US
dc.identifier.citedreferenceMlynarczewska, A., Wysoczanska, B., Karabon, L., Bogunia‐Kubik, K. & Lange, A. ( 2004 ) Lack of IFN‐gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA‐matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplantation, 34, 339 – 344.en_US
dc.identifier.citedreferenceMullighan, C., Heatley, S., Doherty, K., Szabo, F., Grigg, A., Hughes, T., Schwarer, A., Szer, J., Tait, B., To, B. & Bardy, P. ( 2004 ) Non‐HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem‐cell transplantation. Transplantation, 77, 587 – 596.en_US
dc.identifier.citedreferenceNash, R.A., Antin, J.H., Karanes, C., Fay, J.W., Avalos, B.R., Yeager, A.M., Przepiorka, D., Davies, S., Petersen, F.B., Bartels, P., Buell, D., Fitzsimmons, W., Anasetti, C., Storb, R. & Ratanatharathorn, V. ( 2000 ) Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft‐versus‐host disease after marrow transplantation from unrelated donors. Blood, 96, 2062 – 2068.en_US
dc.identifier.citedreferenceNguyen, Y., Al‐Lehibi, A., Gorbe, E., Li, E., Haagenson, M., Wang, T., Spellman, S., Lee, S.J. & Davidson, N.O. ( 2010 ) Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease‐associated markers on GVHD incidence or other adverse outcomes in T‐replete, unrelated donor transplantation. Blood, 115, 3625 – 3631.en_US
dc.identifier.citedreferenceNordlander, A., Uzunel, M., Mattsson, J. & Remberger, M. ( 2002 ) The TNFd4 allele is correlated to moderate‐to‐severe acute graft‐versus‐host disease after allogeneic stem cell transplantation. British Journal of Haematology, 119, 1133 – 1136.en_US
dc.identifier.citedreferenceNorlin, A.C. & Remberger, M. ( 2011 ) A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 86, 57 – 66.en_US
dc.identifier.citedreferenceOrdemann, R., Hutchinson, R., Friedman, J., Burakoff, S.J., Reddy, P., Duffner, U., Braun, T.M., Liu, C., Teshima, T. & Ferrara, J.L. ( 2002 ) Enhanced allostimulatory activity of host antigen‐presenting cells in old mice intensifies acute graft‐versus‐host disease. The Journal of clinical investigation, 109, 1249 – 1256.en_US
dc.identifier.citedreferencePaczesny, S., Krijanovski, O.I., Braun, T.M., Choi, S.W., Clouthier, S.G., Kuick, R., Misek, D.E., Cooke, K.R., Kitko, C.L., Weyand, A., Bickley, D., Jones, D., Whitfield, J., Reddy, P., Levine, J.E., Hanash, S.M. & Ferrara, J.L. ( 2009 ) A biomarker panel for acute graft‐versus‐host disease. Blood, 113, 273 – 278.en_US
dc.identifier.citedreferencePaczesny, S., Braun, T., Lugt, M.V., Harris, A., Fiema, B., Hernandez, J., Choi, S., Kitko, C., Magenau, J., Yanik, G., Peres, E.M., Pawarode, A., Mineishi, S., Whitfield, J., Jones, D., Couriel, D., Reddy, P., Hanash, S., Ferrara, J.L.M. & Levine, J.E. ( 2010a ) Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II‐IV Acute Graft‐Versus‐Host Disease. Blood (ASH Annual Meeting Abstracts), 116, 675.en_US
dc.identifier.citedreferencePaczesny, S., Braun, T.M., Levine, J.E., Hogan, J., Crawford, J., Coffing, B., Olsen, S., Choi, S.W., Wang, H., Faca, V., Pitteri, S., Zhang, Q., Chin, A., Kitko, C., Mineishi, S., Yanik, G., Peres, E., Hanauer, D., Wang, Y., Reddy, P., Hanash, S. & Ferrara, J.L. ( 2010b ) Elafin is a biomarker of graft‐versus‐host disease of the skin. Science Translational Medicine, 2, 13ra12.en_US
dc.identifier.citedreferencePravica, V., Perrey, C., Stevens, A., Lee, J.H. & Hutchinson, I.V. ( 2000 ) A single nucleotide polymorphism in the first intron of the human IFN‐gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN‐gamma production. Human Immunology, 61, 863 – 866.en_US
dc.identifier.citedreferencePulsipher, M.A., Chitphakdithai, P., Logan, B.R., Leitman, S.F., Anderlini, P., Klein, J.P., Horowitz, M.M., Miller, J.P., King, R.J. & Confer, D.L. ( 2009 ) Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34 +  cell dose. Blood, 114, 2606 – 2616.en_US
dc.identifier.citedreferenceRatanatharathorn, V., Nash, R.A., Przepiorka, D., Devine, S.M., Klein, J.L., Weisdorf, D., Fay, J.W., Nademanee, A., Antin, J.H., Christiansen, N.P., van der Jagt, R., Herzig, R.H., Litzow, M.R., Wolff, S.N., Longo, W.L., Petersen, F.B., Karanes, C., Avalos, B., Storb, R., Buell, D.N., Maher, R.M., Fitzsimmons, W.E. & Wingard, J.R. ( 1998 ) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft‐versus‐host disease prophylaxis after HLA‐identical sibling bone marrow transplantation. Blood, 92, 2303 – 2314.en_US
dc.identifier.citedreferenceRemberger, M., Ringden, O. & Markling, L. ( 1995 ) TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplantation, 15, 99 – 104.en_US
dc.identifier.citedreferenceRemberger, M., Persson, U., Hauzenberger, D. & Ringden, O. ( 2002 ) An association between human leucocyte antigen alleles and acute and chronic graft‐versus‐host disease after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 119, 751 – 759.en_US
dc.identifier.citedreferenceRemberger, M., Mattsson, J., Hassan, Z., Karlsson, N., LeBlanc, K., Omazic, B., Okas, M., Sairafi, D. & Ringden, O. ( 2008 ) Risk factors for acute graft‐versus‐host disease grades II‐IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transpl, 41, 399 – 405.en_US
dc.identifier.citedreferenceRitchie, D., Seconi, J., Wood, C., Walton, J. & Watt, V. ( 2005 ) Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft‐versus‐host disease after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 11, 706 – 712.en_US
dc.identifier.citedreferenceRocha, V., Wagner, J.E. Jr., Sobocinski, K.A., Klein, J.P., Zhang, M.J., Horowitz, M.M. & Gluckman, E. ( 2000 ) Graft‐versus‐host disease in children who have received a cord‐blood or bone marrow transplant from an HLA‐identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. New England Journal of Medicine, 342, 1846 – 1854.en_US
dc.identifier.citedreferenceRocha, V., Franco, R.F., Porcher, R., Bittencourt, H., Silva, W.A. Jr., Latouche, A., Devergie, A., Esperou, H., Ribaud, P., Socie, G., Zago, M.A. & Gluckman, E. ( 2002 ) Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA‐identical sibling bone marrow transplantation. Blood, 100, 3908 – 3918.en_US
dc.identifier.citedreferenceRocha, V., Porcher, R., Fernandes, J.F., Filion, A., Bittencourt, H., Silva, W. Jr., Vilela, G., Zanette, D.L., Ferry, C., Larghero, J., Devergie, A., Ribaud, P., Skvortsova, Y., Tamouza, R., Gluckman, E., Socie, G. & Zago, M.A. ( 2009 ) Association of drug metabolism gene polymorphisms with toxicities, graft‐versus‐host disease and survival after HLA‐identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia, 23, 545 – 556.en_US
dc.identifier.citedreferenceRosenblatt, J., Bissonnette, A., Ahmad, R., Wu, Z., Vasir, B., Stevenson, K., Zarwan, C., Keefe, W., Glotzbecker, B., Mills, H., Joyce, R., Levine, J.D., Tzachanis, D., Boussiotis, V., Kufe, D. & Avigan, D. ( 2010 ) Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplantation, 45, 1463 – 1468.en_US
dc.identifier.citedreferenceSairafi, D., Uzunel, M., Remberger, M., Ringden, O. & Mattsson, J. ( 2008 ) No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transpl, 41, 961 – 964.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh12142.pdf
Size:
543.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.